Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract.

Abstract

We analysed the treatment outcome of localized extranodal NK/T cell lymphoma initially treated with CEOP-B chemotherapy based on the primary site of involvement (nasal cavity vs. upper aerodigestive tract) and treatment modality (chemotherapy vs. chemotherapy followed by radiotherapy. Forty-three patients newly diagnosed as extranodal NK/T cell lymphoma were analysed: 29 cases from nasal cavity/nasopharynx and 14 from upper aerodigestive tract. Twenty-six patients were treated with chemotherapy alone, while adjuvant radiotherapy was given to 17 patients. Overall response rate to front-line CEOP-B chemotherapy was 67.4% (29/43) and the complete remission (CR) rate was 44.2% (19/43). Median overall and disease-free survival was 26.87 months [95% confidence interval (CI) = 8.71 - 45.03] and 15.27 months (95% CI = 2.92 - 27.62). The responders (CR or partial response) to initial CEOP-B chemotherapy showed longer overall survival than non-responders (P = 0.0026). Local relapse was observed to be higher in the chemotherapy alone group compared to the chemoradiotherapy group. Adjuvant radiotherapy failed to improve survival; thus, the median disease-free survival of the chemotherapy and chemoradiotherapy groups was not different (P = 0.9101). There may be a tendency for better overall survival in group of upper aerodigestive tract lymphoma than the nasal cavity/nasopharynx group (P = 0.0643). However, front-line CEOP-B chemotherapy has a limited role and adjuvant radiotherapy failed to improve survival in localized extranodal NK/T cell lymphoma.

• Authors: Seok Jin Kim, Byung Soo Kim, Chul Won Choi, Hee Yun Seo, Hye Ryoung Seol, Hwa Jung Sung, In Sun Kim, Chul Yong Kim, Kwang Yoon Jung, Jun Suk Kim
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 47 Issue 7 Pg. 1265-73 (Jul 2006) ISSN: 1042-8194 [Print] United States
• PMID: 16923556 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Bleomycin
• Epirubicin
• Vincristine
• Cyclophosphamide
• Prednisone

Topics

• Adult
• Aged
• Antineoplastic Agents (pharmacology)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Bleomycin (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Disease Progression
• Disease-Free Survival
• Epirubicin (administration & dosage)
• Female
• Humans
• Killer Cells, Natural (cytology)
• Lymphoma, T-Cell (drug therapy, pathology)
• Male
• Middle Aged
• Prednisone (administration & dosage)
• Proportional Hazards Models
• Recurrence
• Remission Induction
• Time Factors
• Treatment Outcome
• Vincristine (administration & dosage)